Inclusion Criteria:  Presenting with histological(by core needle biopsy or by limited incisional biopsy) proven hormone receptor positive (ER≥10% and/or PR ≥1%), HER2 negative(IHC ≤2+ and/or FISH-) , stage II/ III breast cancer. Have clinical indication for neoadjuvant therapy. HER4 IHC score ≥ 4. Measurable disease (breast and/or lymph nodes). The Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1. Adequate bone marrow function (within 4 weeks prior to registration): WBC≥3.0x109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l. Adequate liver function (within 4 weeks prior to registration): bilirubin ≤1.5 x upper limit of normal (UNL) range, ALAT and/or ASAT ≤2.5 x UNL, Alkaline Phosphatase ≤5 x UNL. Adequate renal function (within 4 weeks prior to registration): the calculated creatinine clearance should be ≥50 ml/min. Patients must have the ability to swallow oral medication. Without history of any kind of treatment to known malignancy (solid tumor or hematologic). Written informed consent. Accessible for treatment and follow-up.  Exclusion Criteria:  Evidence of stage IV breast cancer. Contralateral invasive breast cancer or Inflammatory breast cancer. History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization. Known metastatic disease from any malignancy (solid tumor or hematologic). Serious other diseases as infections (hepatitis B, C and HIV), recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias or on screening, any of the following cardiac parameters: bradycardia (heart rate <50 at rest) or QTcF ≥450 msec. Known hypersensitivity reaction to any of the components of the treatment. Pregnancy or lactation at the time of randomization. Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.